Johnson & Johnson (JNJ HM) stock market data APIs
€210.7386
1.93(0.9%)
as of March 17, 2026
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.HM.
Prev. Close
210.7386
Open
212.6717
High
212.7332
Low
210.6958
52 wk Range
125.768-212.85
Market Cap
385 769 M
Dividends (Yield)
0.0224
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
Analysis-TrumpRx lists many medicines at prices higher than paid in UK
By Bhanvi Satija and Michael Erman March 18 (Reuters) - U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is...
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
Pfizer PFE is one of the leading oncology drugmakers with a strong presence across breast, genitourinary, thoracic, gastrointestinal and blood cancers. The company has a well-established portfolio of ...
J&J or Merck? Key Factors Investors Must Weigh Right Now
Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison. Both companies have established strengths in oncology, immunology a...
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that me...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
